Conatus Pharmaceuticals
San Diego
About Conatus Pharmaceuticals
Conatus Pharmaceuticals is a privately-held biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. Their lead program, CTS-1027, is currently undergoing Phase 2 clinical trials for the treatment of Hepatitis C Virus (HCV). Conatus licensed CTS-1027 from Hoffmann-La Roche in 2006, and to date its development has been the primary focus of the Company.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $62.1M
- Funding stage: M&A
- Last round: Series Unknown (Jun 2013)
- Ticker: nasdaq:CNAT
- Website: conatuspharma.com
- Phone: 8585588920
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/conatus-pharmaceuticals-2630018 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.